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ARTICLE
TBX22 Missense Mutations Found in Patients with X-Linked Cleft
Palate Affect DNA Binding, Sumoylation, and Transcriptional
Repression
Artemisia M. Andreou,* Erwin Pauws,* Marius C. Jones, Manvendra K. Singh, Markus Bussen,
Kit Doudney, Gudrun E. Moore, Andreas Kispert, Jan J. Brosens, and Philip Stanier
The T-box transcription factor TBX22 is essential for normal craniofacial development, as demonstrated by the finding
of nonsense, frameshift, splice-site, or missense mutations in patients with X-linked cleft palate (CPX) and ankyloglossia.
To better understand the function of TBX22, we studied 10 different naturally occurring missense mutations that are
phenotypically equivalent to loss-of-function alleles. Since all missense mutations are located in the DNA-binding T-box
domain, we first investigated the preferred recognition sequence for TBX22. Typical of T-box proteins, the resulting
sequence is a palindrome based around near-perfect copies of AGGTGTGA. DNA-binding assays indicate that missense
mutations at or near predicted contact points with the DNA backbone compromise stable DNA-protein interactions. We
show that TBX22 functions as a transcriptional repressor and that TBX22 missense mutations result in impaired repression
activity. No effect on nuclear localization of TBX22 was observed. We find that TBX22 is a target for the small ubiquitin-
like modifier SUMO-1 and that this modification is required for TBX22 repressor activity. Although the site of SUMO
attachment at the lysine at position 63 is upstream of the T-box domain, loss of SUMO-1 modification is consistently
found in all pathogenic CPX missense mutations. This implies a general mechanism linking the loss of SUMO conjugation
to the loss of TBX22 function. Orofacial clefts are well known for their complex etiology and variable penetrance, involving
both genetic and environmental risk factors. The sumoylation process is also subject to and profoundly affected by similar
environmental stresses. Thus, we suggest that SUMO modification may represent a common pathway that regulates
normal craniofacial development and is involved in the pathogenesis of both Mendelian and idiopathic forms of orofacial
clefting.
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Orofacial clefts affecting the lip and/or palate are frequent
birth defects, affecting between 1 in 700 and 1 in 2,000
births worldwide.1 Despite being a common anomaly, the
etiology is highly complex, involving both genetic and
environmental risk factors, but the molecular basis re-
mains largely unknown. Efforts to identify the genetic fac-
tors have been most successful for monogenic, syndromic
clefts, such as in Van der Woude syndrome (involving
IRF6); Margarita Island syndrome (PVRL1); Kallmann syn-
drome (FGFR1); ectrodactyly, ectodermal dysplasia, and
cleft lip and/or palate syndrome (p63); cleft lip and/or
palate with hypodontia (MSX1); and X-linked cleft palate
(TBX22).2,3 Phenotypic penetrance within families is often
variable, and it is clear that mutations in these genes may
contribute to a proportion of the nonsyndromic cleft
cases.3 Studies show that mutations in TBX22 represent
the most common single cause of cleft palate known (caus-
ing 4% of cases) and also are found in patients with iso-
lated defects or a family history too small to indicate X
linkage.4 X-linked cleft palate (CPX [MIM 303400]) is a
semidominant defect characterized by an isolated cleft of
the secondary palate, usually but not always accompanied
by ankyloglossia (tongue-tie). CPX is caused by mutations
in the T-box gene TBX22.4–7 Mutations may be nonsense,
frameshift, splice-site, or missense changes, the last af-
fecting only the T-box domain and apparently equivalent
to functional null alleles. T-box proteins like TBX22 share
a highly conserved DNA-binding domain of ∼180 aa,
which, in most cases, preferentially recognizes DNA con-
taining one or more copies of the consensus sequence 5′-
AGGTGTGA-3′, initially identified for Brachyury.8 Multi-
ple copies of this T-box binding element (TBE) may be
arranged with different spacing and orientations, affecting
the binding specificity.9 Apart from TBX22, loss-of-func-
tion mutations have been described for other T-box–
related diseases, such as for ulnar-mammary syndrome
(TBX3 mutations)10 and Holt-Oram syndrome (TBX5
mutations).11,12 Despite clear phenotypic variability, often
within single families, a functional equivalence for dif-
ferent mutation types has been observed.13,14 Similarly,
variable severity is frequently observed between family
members who carry the same TBX22 mutation, implicat-
ing a role for either genetic background or different en-
vironmental factors. Again, this finding does not correlate
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with mutation type, suggesting that missense mutations
are equivalent to nonsense or splice-site changes. Because
it is an X-linked condition, these mutations are likely to
result in a complete loss of function in affected males.5
The functional effect of mutations has been extensively
studied for TBX5, showing that the precise localization
within the protein can have a profound effect on DNA
binding, nuclear localization, and interaction with cofac-
tors or binding partners.15–17
Here, we identify the transcriptional role of TBX22, its
regulation, and the functional effect of naturally occurring
pathogenic missense mutations. We find that TBX22 acts
as a transcriptional repressor and is capable of autoregu-
lating its expression through the distal TBX22 promoter,
similar to what was shown for TBX5.18 We show that DNA
binding and transcriptional repression, but not subcellular
localization, are compromised by CPX mutations. Post-
translational modification with the small ubiquitin-like
modifier protein SUMO is a dynamic and reversible pro-
cess that affects many proteins, modulating protein sta-
bility, protein-protein interactions, and cellular localiza-
tion.19 SUMO modification of transcription factors is most
commonly associated with inhibition of transcription.20
Previously, the transcriptional repressor TBX2 was indi-
rectly associated with sumoylation through the identifi-
cation of an interaction with the SUMO-conjugating
enzyme UBC-9.21 Here, we present direct evidence that
TBX22 undergoes SUMO-1 conjugation and show that this
modification is required for transcriptional repression. The
dominant repression domain within TBX22 maps to the
N-terminal region, which also contains the lysine (K63)
residue to which SUMO-1 attachment occurs. Despite the
fact that the missense mutations we investigated are re-
mote from this site, we find that they all cause a marked
down-regulation or absence of SUMO-1 conjugation. This
provides a common mechanism mediating the loss of
TBX22 activity due to missense mutation and suggests
that both DNA binding–dependent and DNA binding–
independent effects may converge in patients with CPX.
Material and Methods
Expression Vectors
Plasmids expressing full-length TBX22 were prepared by ligating
a PCR fragment spanning the full-length ORF into the cloning
vector pcDNA3T/A-TOPO (Invitrogen) (pcDNA3.1.TBX22.V5/
His), pSP64G (pSP64G.TBX22.myc), or pCI-GAL4 (pCI.GAL4-
TBX22). All pGL3-hP0 constructs were prepared by ligating ap-
propriate PCR-generated TBX22 promoter fragments into the
pGL3-basic vector (Promega). Plasmids used in the GAL4 lucif-
erase reporter assay (LexA-GAL4-luc and LexA-VP16) were gen-
erously provided by Dr. M. Christian (Imperial College London).
In Vitro Coupled Transcription-Translation
TBX22 wild-type and mutant proteins were expressed from the
pSP64G.TBX22.myc construct, by use of the T7-coupled tran-
scription-translation reticulocyte lysate system (Promega), in ac-
cordance with the manufacturer’s instructions. Reactions that
were not used immediately after incubation were stored at80C,
with the addition of glycerol to 10%. Protein synthesis and con-
centration standardization were assessed using SDS-PAGE and
western blotting with anti-myc antibody (Roche Molecular
Biochemicals).
Western Blotting and Coimmunoprecipitation
Whole-cell protein extracts were obtained by lysing cells in re-
ducing SDS-PAGE loading buffer heated to 85C, followed by son-
ication. Proteins were resolved by SDS-PAGE, were transferred to
a polyvinylidene fluoride membrane, were blocked in milk, and
were probed with anti-V5 antibody (Invitrogen) and an appro-
priate secondary antibody. Bands were visualized using the ECL
Plus Western Blotting detection system (Amersham). Coimmu-
noprecipitation studies were performed in COS-1 cells transfected
with pcDNA3.1.TBX22.V5/His and either SUMO-1 wild-type or
SUMO-1 mutant constructs. Cells were scraped in lysis buffer (20
mM Tris-HCl, 300 mM NaCl, 1% NP-40, 10 mM N-ethylmaleim-
ide, and 1# Complete protease inhibitors [Roche]) and were cen-
trifuged at 13,000 rpm at 4C for 5 min. Protein concentrations
of the supernatants were standardized by Bradford assays, and 1
mg was used for the immunoprecipitation. TBX22–SUMO-1 com-
plexes were precipitated on protein A/G agarose beads (Sigma)
with rabbit polyclonal anti-TBX22 antibody (custom-made at
CovalAb [AbCam]).
Binding-Site Selection and Electrophoretic Mobility Shift
Assay (EMSA)
The binding-site selection assay was performed as described else-
where,8 by use of in vitro translated full-length TBX22.myc pro-
tein (pSP64G.TBX22.myc) and anti-myc antibody (Roche Molec-
ular Biochemicals) or TBX22.V5 protein (pcDNA3.1.TBX22.V5/
His) and anti-V5 antibody (Invitrogen). Sequences of DNA
fragments isolated after four rounds of selection were then
aligned to generate a consensus sequence. Double-stranded DNA
containing the TBX22 consensus binding site was produced by
annealing oligonucleotides 5′-CTAGCAAGGTGTGAAATTGTCA-
CCTCAA-3′ and 5′-GTTCCACACTTTAACAGTGGAGTTTCGA-3′.
The Brachyury consensus sequence and the T1/2 site were as de-
scribed elsewhere.8 Annealed oligonucleotides were end labeled
with [32P]-gATP and were purified on Sephadex G-25 columns.
For the protein-DNA binding reactions, 2–6 ml of TBX22 protein
was added to 0.05 pmol of double-stranded DNA, in 20 ml binding
buffer (25 mM HEPES, 75 mM NaCl, 10% glycerol, 0.1% NP-40,
1 mM MgCl2, 1 mM phenylmethanesulphonyl fluoride, and 0.25
mM EDTA), containing Complete Protease Inhibitors (Roche Mo-
lecular Biochemicals), 1 mg/ml BSA, and 1 mg of poly(dI.dC). For
antibody supershift assays, 1 ml of monoclonal anti-myc antibody
was added to appropriate reactions. All samples were resolved by
electrophoresis on 4.5% polyacrylamide gels in 1# Tris-glycine
buffer. After electrophoresis, the gels were dried, and bands were
visualized by autoradiography.
Site-Directed Mutagenesis
Plasmid constructs containing mutated full-length TBX22 cDNA
were produced using the QuickChange site-directed mutagenesis
kit (Stratagene). A series of 10 mutants, mirroring missense
changes identified in patients with CPX (table 1), were generated
in both pSP64G.TBX22.myc (for in vitro translation) and
pcDNA3.1.TBX22.V5/His (for transfection) constructs. Lysine sin-
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Table 1. Functional Analysis of Natural TBX22 Missense Mutations
Missense
Mutationa
Location
in T-Box
Domain
DNA-Binding
Abilityb
Promoter
Repressionb Sumoylationb
Wild type …   
W102C a Helix 1  / 
G118C DNA contact /  
R120W DNA contact   
M121V Close to DNA contact /  
P183L Dimerization contact /  
C184F Dimerization contact /  
E187K a Helix 2   
L214P Close to DNA contact   /
T260M DNA contact   /
N264Y Close to DNA contact   /
a These missense mutations had nuclear subcellular localization.
b  p present; / p weak;  p absent.
gle mutants (K54R, K63R, and K271R) in pcDNA3.1.TBX22.V5/
His were generated in a similar way for SUMO analysis. Primer
sequences are available on request.
Cell Culture, Transfections, and Luciferase Reporter Assays
293T, T47D, HeLa, or COS-1 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum, 2 mM L-glutamine, nonessential amino acids, and
antibiotics. Transfections were performed in 96-well or 6-well
plates by use of FuGene reagent (Roche) in accordance with the
manufacturer’s instructions. Firefly and Renilla luciferase activi-
ties were measured using the luclite Luciferase Reporter Gene
Assay System (Perkin Elmer) on a Fluostar Optima plate reader
(BMG Labtech).
RT-PCR
RNA was isolated using Trizol reagent (Invitrogen) in accordance
with the manufacturer’s instructions. First-strand cDNAs were
synthesized with Moloney murine leukemia virus–reverse tran-
scriptase and random hexamers (Promega) as described else-
where.2 PCR was then performed using Taq polymerase (Bioline),
by use of primer pairs for TBX22 and b-ACTIN, generating PCR
fragments of 450 bp and 513 bp, respectively. For TBX22, the
primers were ex5-FOR (5′-AGTGCACGTGATAGAGCAAG-3′) and
ex8-REV (5′-TGTCAACCTGCCCTATGCT-3′); for b-ACTIN, the
primers were FOR (5′-GCCCAGAGCAAGAGAGGCAT-3′) and REV
(5′-GGCCATCTCTTGCTCGAAGT-3′).
Immunostaining Assay
COS-1 cells cultured on coverslips placed at the bottom of each
well were transfected with expression constructs as described
above. After 48 h, transfected cells were fixed in 4% paraformal-
dehyde (PFA) and 125 mM HEPES at 4C for 10 min, followed by
8% PFA at 4C for 50 min and a wash in PBS. For immunolabeling,
fixed cells were incubated with the primary antibody (anti-V5
[Invitrogen]) and then with the secondary antibody, anti-mouse
fluorescein isothiocyonate (FITC) (Jackson Laboratories), in ac-
cordance with standard methods. Coverslips were mounted on
slides in a drop of mounting medium with 4,6-diamidine-2-phen-
ylindole (DAPI) (Vectrashield [Vector Laboratories]). The cells
were then viewed using an Axioskop (Zeiss) fluorescent micro-
scope, by use of 40# objective. Images were captured using a
Hamamatsu Photonics digital camera (ORCA-ER [Hamamatsu])
and were processed using IPLab (v3.70 [Scanalytics]).
Results
TBX22 DNA-Binding Specificity
T-box transcription factors form a protein family based on
the presence of a highly conserved DNA-binding do-
main.22 This domain recognizes a specific DNA target se-
quence or TBE that usually consists of one or more copies
of the minimal 5′-AGGTGTGA-3′ sequence arranged in dif-
ferent orientations and with variable spacing.23 To char-
acterize the binding preference for TBX22, we first per-
formed a binding-site selection assay.8 After four rounds
of selection, 16 DNA fragments were cloned, sequenced,
and aligned, to generate the consensus sequence AGGTG-
TGAAATTGTCACCT (fig. 1A and 1B). This TBX22-specific
TBE represents an imperfect palindrome that is inverted
with respect to the reported Brachyury sequence.8 In con-
trast to the Brachyury TBE, which has no spacer, the half-
sites are separated by 3 nt, and the second half-site con-
tains 2 nt that do not conform to the consensus sequence.
In EMSA, in vitro translated TBX22-myc protein binds to
the TBX22 TBE, causing both a shift and, in the presence
of either anti-myc (fig. 1A) or anti-TBX22 antibodies (data
not shown), a supershift. We also found that TBX22 can
bind weakly to the Brachyury palindrome or to a single
consensus half-site but requires the presence of antibody
to stabilize both interactions (data not shown).
Effect of Missense Mutations on TBX22 DNA Binding
Since all known naturally occurring TBX22 missense
mutations are located within the T-box domain, we
investigated their effect on DNA binding to the TBX22-
specific TBE. We used in vitro mutagenesis to intro-
duce 10 different missense changes into an expression
construct containing the full-length TBX22 sequence
(pSP64G.TBX22.myc). These mutations (fig. 2A) were all
originally identified in patients with CPX4–7 and included
www.ajhg.org The American Journal of Human Genetics Volume 81 October 2007 703
Figure 1. Identification of the TBX22 preferred binding sequence. A, EMSA showing products of labeled double-stranded oligonucleotides
and myc-tagged TBX22 protein after zero, two, and four rounds of selection. Lanes 1p free probe; lanes 2p rabbit reticulocyte lysate;
lanes 3 p rabbit reticulocyte lysate plus anti-myc antibody; lanes 4 p TBX22.myc; lanes 5 p TBX22.myc plus anti-myc antibody. B,
Alignment of sequences from cloned and sequenced DNA fragments after four rounds of selection. The frequency of nucleotides found
at each position is shown, along with the resulting consensus sequence that also represents the most common cloned sequence (7 of
16). Arrows highlight the half-sites comprising the imperfect inverted palindrome.
the previously unpublished mutations W102C, found in
a 5-generation family presenting with isolated, nonsyn-
dromic cleft palate with apparent X linkage, and C184F,
found in a boy with submucous cleft palate and ankylo-
glossia whose mother also had significant ankyloglossia.
In addition, we included a non–disease-causing polymor-
phism, E187K.4,7 Proteins were expressed using an in vitro
translation system and were checked both quantitatively
and qualitatively by western blotting, to standardize input
(fig. 2B). Mutant proteins were then assayed for their abil-
ity to bind to the TBX22 TBE. Apart from the E187K poly-
morphic mutation, all single amino acid substitutions
were found to be sufficient to significantly weaken or abol-
ish DNA binding (fig. 2B and table 1). All mutations at or
very close to highly conserved residues that make direct
contact with the DNA backbone24 showed either complete
loss of binding (R120W, L214P, T260M, and N264Y) or
weaker binding (G118C and M121V) than that of the wild-
type and polymorphic controls, highlighting the struc-
tural importance of the T-box as a DNA-binding domain.
Mutants located in the putative dimerization domain (aa
180–185)24 have a weak effect on DNA binding (P183L
and C184F), compared with controls. The novel W102C
mutation completely loses the ability to bind DNA, but,
since this residue is 11 aa away from the nearest DNA
contact point, its effect may be through destabilizing pro-
tein conformation. Together, these data suggest that lack
of DNA binding contributes significantly to TBX22 loss of
function.
Effect of TBX22 Missense Mutations on Subcellular
Localization
Several missense mutations in TBX5 identified in patients
with Holt-Oram syndrome have been reported to show
impaired protein trafficking and subcellular localization.16
Therefore, we transfected pcDNA3.1.TBX22.V5/His con-
structs encoding the wild-type TBX22 or 1 of the 10 TBX22
mutants into COS-1 cells and examined the subcellular
localization of the expressed proteins by immunostaining
with anti-V5 antibody. We found that wild-type TBX22
and all mutant proteins similarly localize within the nu-
cleus, displaying a diffuse staining pattern with nucleolar
sparing, indicating exclusion from the areas where the
most condensed chromatin is present (fig. 3 and table 1).
Characterization of the TBX22 Promoter
By interrogating genomic and EST sequence databases
(UCSC Genome Browser) and by experimental analysis
using 5′ rapid amplification of cDNA ends6 (data not
shown), we have identified two putative transcription
start sites for TBX22. RT-PCR analysis of human embry-
onic tongue and palatal tissues confirmed both expression
and appropriate splicing of an extended exon 1, adding
at least 25 nt to the 5′ UTR, and of an alternative non-
coding exon 0. This novel 5′ exon is located ∼10 kb up-
stream and splices directly onto exon 1 (fig. 4A and data
not shown). Both transcripts include the same start codon
and identical ORFs. We generated luciferase promoter re-
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Figure 2. Effect of missense mutations identified in a patient with CPX on DNA binding. A, Schematic diagram showing the location
of missense mutations in TBX22. B, EMSA, to demonstrate the ability to shift or supershift the labeled TBX22 TBE probe by use of in
vitro translated TBX22 proteins generated from wild-type (WT) or missense mutant constructs. FPp free probe; RRLp rabbit reticulocyte
lysate control; minus sign () p protein as labeled; plus sign () p protein as labeled plus anti-myc antibody. To ensure equal
loading in each lane, in vitro translated TBX22 proteins were immunoblotted with anti-myc antibody (top panel).
porter constructs in pGL3-basic by cloning 2 kb of se-
quence from the upstream region of each putative tran-
scriptional start site (hP0 and hP1) (fig. 4A). Transient
transfections performed in 293T cells showed promoter
activity for the sense hP0 construct but not for the anti-
sense or hP1 constructs (fig. 4B). To identify a minimal
promoter region, serial deletion constructs were gener-
ated, revealing that a 300-bp region upstream of the pu-
tative start of transcription is sufficient to confer hP0 pro-
moter activity (fig. 4C).
TBX22 As Transcriptional Repressor
In addition to 293T cells, promoter activity of the pGL3-
hP0 construct was also observed in COS-1 cells but not in
HeLa or T47D cells (data not shown). Interestingly, RT-
PCR showed that 293T and COS-1 cell lines were com-
pletely devoid of TBX22 expression, whereas endogenous
expression was readily detected in T47D and HeLa cells
(fig. 5A). Since the minimal hP0 sequence contains several
putative TBEs, including imperfect half-sites and one pal-
indromic sequence, autoregulation—as reported for other
T-box genes, such as HrBra, HrTbx6, and TBX518,25—was
a possible explanation. This prompted us to test the
effect of cotransfecting full-length wild-type TBX22
(pcDNA3.1.TBX22.V5/His) with the minimal pGL3-hP0
promoter into 293T and COS-1 cells. A dose-dependent
repression of hP0 promoter activity was observed, with a
net reduction of ∼60% consistently achieved (fig. 5B). The
lack of complete hP0 promoter inhibition, seen in T47D
and HeLa cells, may reflect either transfection efficiency
or the absence of specific corepressors in cells without
endogenous TBX22 expression. To investigate the repres-
sion activity of TBX22 further, reporter assays were per-
formed using full-length TBX22 fused to the GAL4 DNA-
binding domain (pCI.GAL4-TBX22). In this assay, the
GAL4-TBX22 construct was cotransfected with a luciferase
reporter construct containing one LexA and five GAL4
binding sites upstream of a TATA box (LexA-GAL4-Luc),
together with a LexA-VP16 construct. Through binding of
the LexA sequence, VP16 is able to activate luciferase ex-
pression. No effect was observed when the GAL4 DNA-
binding domain alone was added, but, in the presence of
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Figure 3. Nuclear localization of wild-type and mutant TBX22
constructs. Constructs (pcDNA3.1.TBX22.V5/His) encoding wild-
type (WT) or mutant TBX22 or empty pcDNA3.1-V5/His (Mock) were
transfected into 293T cells. Cells were cultured for 48 h, were fixed,
and were stained with DAPI and anti-V5/FITC.
Figure 4. Identification of TBX22 promoter sequences. A, Sche-
matic diagram of the putative promoters hP0 and hP1 that generate
different transcripts. These were initially identified by bioinfor-
matic analysis of genomic and EST sequence databases and were
confirmed experimentally by RT-PCR analysis. B, pGL3-hP0 (P0)
and pGL3-hP1 (P1) reporter constructs, transfected into 293T cells
together with control pGL3 (white bars indicate sense; black bars
indicate antisense). Minus sign () p empty vector. C, Relative
promoter activity, determined after truncated pGL3-hP0 constructs
were transfected into 293T cells.
GAL4-TBX22, promoter activity is reduced in a dose-de-
pendent manner by up to 80% (fig. 5C). The fact that the
full-length TBX22 protein is able to repress transcription
of the reporter in trans indicates that TBX22 contains at
least one autonomous repression domain. Therefore, we
tested truncated GAL4-TBX22 fragments containing the
N-terminal sequence (aa 1–101), the T-box domain (aa
100–285), and the C-terminal sequence (aa 285–520). The
data show that at least one repression domain is located
in both the N-terminal region and the T-box domain, with
the N-terminal domain having the stronger effect. The C-
terminal region does not repress but instead may weakly
activate transcription at the higher concentration tested
(fig. 5C).
Effect of TBX22 Missense Mutations on Transcriptional
Repression
To investigate how missense mutations found in patients
with CPX affect the function of TBX22, we used the pGL3-
hP0 construct in a reporter assay. As expected, wild-type
TBX22 and the polymorphic E187K variant demonstrated
similar repressor activity, repressing to ∼45% of the basic
promoter activity (fig. 5D). However, repression by the
pathogenic mutants in comparison with wild-type TBX22
was significantly compromised ( , by Student’s t test)P ! .05
(fig. 5D). This effect did not specifically correlate with ei-
ther the position of the missense change within the T-box
domain or DNA-binding ability but rather is a generalized
down-regulation (table 1). Moreover, some mutants, such
as T260M and R120W, attenuated promoter activity de-
spite lack of binding to the consensus motif. Thus, TBX22
activity may not depend entirely on interaction with cis-
regulatory DNA elements but could involve trans-repres-
sion of other transcription factors, possibly different T-box
proteins.26
Posttranslational Modification of TBX22 by SUMO1
Posttranslational modification of transcription factors by
the small ubiquitin-related modifier SUMO-1, in general,
Figure 5. TBX22, which acts as a transcriptional repressor. A, RT-PCR performed using primers in TBX22 exons 5–8, to show endogenous
expression in human cell lines (upper panel), and in b-ACTIN, to confirm RNA integrity and loading (lower panel). Plus signs () and
minus signs () indicate reverse transcriptase–positive and –negative treated samples, respectively. B, Cotransfection of pGL3-hP0 with
increasing amounts (2.5, 10, and 25 ng) of pcDNA3.1.TBX22.V5/His expression construct, performed in 293T cells. WTp wild type. C,
293T cells, cotransfected with a luciferase reporter construct containing GAL4 and LexA binding sites. The addition of LexA-VP16 to
the transfection results in activation of the basic promoter. Addition of increasing amounts (1 and 10 ng) of full-length GAL4-TBX22,
N-terminal (1–101), and T-box (100–285) constructs demonstrate dose-dependent repression, whereas the C-terminal (285-520) fusion
construct demonstrates inactivity or slight activation. D, Repression of pGL3-hP0 by wild-type TBX22 was compared with that of natural
missense mutations found in patients with CPX. Different experiments were compared by normalizing to the basal promoter activity of
pGL3-hP0 (100%). Dotted lines represent maximal and minimal activity. Relative promoter activity was determined by normalizing the
luciferase values to the internal control cytomegalovirus-Renilla, and each bar is representative of an experiment done in quadruplicate
and on at least three separate occasions.
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Figure 6. Posttranslational modification of TBX22 by SUMO-1. A,
Western-blot analysis of protein extracts from COS-1 cells trans-
fected with pCDNA3.1.TBX22-V5/His only and with wild-type
SUMO1-GG-HSTV or inactive SUMO1-DGG mutant. B, Western blots
showing coimmunoprecipitation of TBX22.V5 and SUMO-1 wild-
type or mutant after transfection into COS-1 cells. The interaction
of TBX22 with wild-type SUMO-1 can be visualized with both anti–
SUMO-1 and anti-V5 antibodies. M p molecular-weight marker.
bestows repressive properties.27 We therefore investigated
whether TBX22 is subject to sumoylation. Indeed, western
blotting of protein extracts from COS-1 cells transfected
with a full-length TBX22 construct (pcDNA3.1.TBX22.V5/
His) by use of an anti-V5 antibody shows a higher–
molecular-weight species consistent with SUMO modifi-
cation. The intensity of this band increases on coexpres-
sion of wild-type SUMO-1 (SUMO-1-GG-HSTV) but not
with the inactive SUMO1-DGG mutant (fig. 6A). Coim-
munoprecipitation of the putative TBX22-SUMO complex
by use of polyclonal anti-TBX22 followed by anti-SUMO-
1 antibodies confirmed that the slower-migrating band
corresponds to covalent modification by SUMO-1 (fig. 6B).
Necessity of Sumoylation for Transcriptional Repression
On the basis of the minimal consensus motif WKXE/D, in
which W is a large hydrophobic residue and K is the lysine
to which SUMO is added,28 we identified three putative
sumoylation sites in TBX22 (fig. 7A). Two of these (K63
and K271) are conserved between human and mouse.
Each site was mutated individually (K54R, K63R, and
K271R), to examine the effect on SUMO-1 conjugation.
Interestingly, mutation of the evolutionarily conserved
sites K63 and K271 completely abrogates and attenuates
sumoylation, respectively (fig. 7A). In contrast, mutation
of the nonconserved lysine (K54) has no effect. Moreover,
both K63R and K271R mutants (but not K54R) lose the
ability to repress in the pGL3-hP0 promoter assay (fig. 7B).
However, we did not find any evidence of a higher–
molecular-weight species consistent with SUMO attach-
ment at two sites. According to the three-dimensional
structure of Brachyury,24 K271 (K205 in Brachyury) is
within the a-helix 3 that directly bridges the DNA back-
bone and is next to I206 (I272 in TBX22), which forms
hydrophobic contacts with a guanine residue of the target
sequence. EMSA showed complete loss of binding for
K271R to the TBX22 TBE, whereas K54R and K63R, which
lie outside of the T-domain, bind as strongly as the wild
type (fig. 7C). This suggests that K271R has DNA binding–
dependent loss of repression, whereas, for K63R, binding
is normal and loss of repression is SUMO dependent. To
confirm that loss of TBX22 transcriptional repression can
be SUMO dependent, we investigated the effect of de-
sumoylating TBX22. Cotransfection with SUMO-specific
peptidases (SENPs) in the hP0 promoter repression assay
showed that SENP2, but not SENP1, completely abolishes
repression (fig. 8A). Apparent effects enhancing repression
and activation for SENP1 and SENP2, respectively, are not
significant and can be explained by their generalized ef-
fects on the basal transcriptional machinery (data not
shown). Western blots to examine TBX22 sumoylation
show that SUMO-conjugated TBX22 is significantly re-
duced by increasing concentrations of SENP2 but not
SENP1. In addition, the stability of unconjugated TBX22
and the sumoylated form are distinctly reduced in cells
overexpressing SENP2 (fig. 8B).
Effect of TBX22 Missense Mutations on Sumoylation
Next, we investigated the sumoylation status of the mis-
sense mutants. Unexpectedly, we found that all the mu-
tants but not the E187K variant either fail to conjugate or
have markedly reduced levels of SUMO conjugation (fig.
8C and table 1), even in the presence of overexpressed
SUMO-1 (data not shown). The reduced sumoylation seen
for L214P, T260M, and N264Y may reflect their position
and conservation within the T-box domain, which is sim-
ilar to that of the lysine mutant K271R shown above. De-
spite the disparate location of the various missense mu-
tations throughout the T-box domain, impaired SUMO-1
conjugation is a consistent finding that may suggest a
common mechanism for loss of TBX22 function indepen-
dent of DNA-binding ability.
Discussion
The CPX phenotype caused by mutations in TBX22 most
likely results from a loss of protein function.5 This can be
simply explained in cases where a severely truncated pro-
tein results from the introduction of a premature stop co-
don, either through nonsense, splice-site, or frameshift
sequence changes. Missense mutations, however, have a
much less dramatic structural effect on the protein but
can be equally potent functionally. In this study, we in-
vestigated the effects of naturally occurring missense mu-
tations on direct DNA binding, subcellular localization,
and transcriptional activity. Although TBX22 has both re-
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Figure 7. Effect of SUMO-1 conjugation on TBX22 activity. A, Sequence alignment of human and mouse TBX22, highlighting the
position of the three SUMO consensus attachment motifs (WKXE/D) found in the human sequence. Asterisks (*) mark the lysine residues
at putative SUMO attachment sites K54, K63, and K271. Western-blot analysis with anti-V5 antibody shows sumoylation of wild-type
(WT), K54R, and K271R mutant constructs. K63R is not modified even when SUMO is overexpressed. B, Effect of lysinerarginine
mutations in TBX22 on hP0 promoter activity. C, EMSA showing effect of K54R, K63R, and K271R mutations on DNA binding compared
with the wild type. FP p free probe; RRL p rabbit reticulocyte lysate negative control; minus sign () p without addition of anti-
V5; plus sign () p with addition of anti-V5.
pression and activation domains, we found that the over-
riding effect in our cell-based assays is transcriptional
repression and that posttranslational modification by
SUMO-1 is an absolute requirement for this activity. Com-
pared with the wild type, mutants had no effect on sub-
cellular localization but variably compromised DNA bind-
ing and the ability to conjugate to SUMO-1. Both have a
marked effect on transcriptional repression and suggest
that complex regulation of downstream target interaction
is required to achieve normal function.
In patients with CPX, missense changes are found
exclusively within the T-box DNA-binding domain, sug-
gesting defective binding to target promoter sequences as
a common mechanism. To investigate this, we generated
both in vitro and in vivo assays. To test DNA binding
directly, an optimal or preferential DNA-binding sequence
was first determined using the binding-site selection
method.8 The resulting sequence, which closely resembles
the Brachyury palindrome, binds strongly to TBX22 in
EMSA but is not a naturally occurring sequence in the
human genome. It is more likely that half-sites alone or
multiple sites that are at a distance but are brought into
close proximity by DNA folding will represent the true
binding sites in vivo.29 Nevertheless, the TBX22 TBE allows
comparison of DNA-binding ability between wild-type
and mutant proteins. As expected, the binding ability of
all the mutants was affected to some extent, but, whereas
some of the mutants completely failed to bind DNA, oth-
ers bound weakly or showed only slight differences com-
pared with the wild-type protein, potentially reflecting
their various roles in DNA contact or protein-protein
interactions.
Mutations identified in other T-box genes have also
been shown to have similar effects on DNA-binding be-
havior. Loss of DNA binding was most notable at or close
to sites predicted to interact directly with the DNA se-
quence. One of the TBX22 mutations, G118C, occurs at
the same position within the T-box as G80R, a mutation
in TBX5 found in a patient with Holt-Oram syndrome.15
Whereas the TBX5 mutation completely abolishes15 or dra-
matically reduces16 the ability of the protein to bind DNA,
TBX22 G118C still binds, although less effectively than
the wild type. This difference could be either because of
structural differences between the two proteins or because
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Figure 8. Profound affect of missense mutations on TBX22–SUMO-1 conjugation. A, Effect of cotransfecting SENP1 and SENP2 on hP0
promoter activity repression by TBX22. WT p wildtype. B, Western blots with anti-V5 antibody, showing cotransfections of TBX22-V5
constructs with increasing concentrations of SENP1 and SENP2 (top panel). The middle panel confirms the expression of the SENP1 and
SENP2 proteins by use of an anti-FLAG antibody. The third panel shows a decrease of total SUMO-1 conjugates and a rise in free SUMO-
1 levels with increased SENP concentration. A control for equal loading was performed using anti–b-actin antibody (bottom panel). C,
Western blotting of transfected TBX22-V5 proteins containing natural missense mutations with anti-V5 antibody (top panel). Approx-
imately even levels of endogenous SUMO-1 conjugates are seen in each lane (bottom panel).
the glycine is substituted for cysteine in TBX22 and ar-
ginine in TBX5. G118C as well as R120W and M121V
mutations are found within a conserved nuclear locali-
zation signal (NLS) reported for TBX5, in which the equiv-
alent of arginine 120 is an essential basic residue.30 Similar
to G80R in TBX5,16 however, nuclear localization of TBX22
is not impaired, as might have been expected for these
mutants. Alternatively, a predicted NLS (KRKLQ) is found
in the N-terminal region of TBX22, which is conserved in
its most closely related T-box family members: TBX15 and
TBX18. This sequence is not disturbed by any of the mis-
sense mutations tested but will be investigated in further
studies.
Our data strongly suggest that dynamic posttransla-
tional modification of TBX22 by SUMO-1 is a requirement
for normal function. Missense mutations in the T-box
domain down-regulate SUMO-1 attachment and have a
marked effect on DNA-binding ability. However, there is
an incomplete correlation between these findings that
suggests a certain degree of independence. The EMSA per-
formed with the preferred TBE presents an artificial assay
that may be particularly sensitive to specific amino acid
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changes. In contrast, the reporter assay using the hP0
promoter sequence shows evidence of DNA binding–
independent repression (by EMSA) for several mutations
(W102C, R120W, and T260M), whereas P183L binds DNA
but abolishes repression. Although sumoylation does not
appear to be required for DNA binding (e.g., K63R), it is
possible that, at the cellular level, either DNA binding or
perhaps subnuclear localization to the appropriate tran-
scriptional compartment might be required for SUMO at-
tachment. This could be the result of a subtle effect on
protein conformation caused by mutations in the T-box
domain, which either limit access to the site of SUMO
attachment or hinder interaction with specific SUMO E3
ligases.
Among T-box proteins, K63 is a unique residue con-
served only in TBX22 orthologs. K271, on the other hand,
is found ubiquitously throughout the T-box protein fam-
ily. Therefore, if K271 is a SUMO attachment site, it might
be predicted that many other T-box genes would be mod-
ified in the same way. In fact, the consensus motif at this
site has been suggested elsewhere as a putative SUMO at-
tachment site for Tbx2.21 However, our data show that
K271 is not the SUMO attachment site for TBX22. Fur-
thermore, we also have preliminary data (not shown) sug-
gesting that TBX2 is indeed modified by SUMO, whereas
TBX1, TBX15, TBX18, and Brachyury are not. In TBX22
at least, it would seem that K63 is the unique SUMO at-
tachment site, whereas K271 is required for DNA binding
and affects SUMO conjugation through some as-yet-
unknown mechanism.
It is very interesting to note that several other proteins
that are directly associated with the human cleft lip and/
or palate defects have recently been shown to be sumoy-
lated, including those encoded by MSX1, SATB2, and
P63.31–33 SUMO modification has also been described for
a number of other genes that are linked to craniofacial
development, either by their expression pattern or because
the classic mouse mutant phenotype has an orofacial cleft,
including SOX9, SMAD4, and EYA1.34–36 Furthermore, a pa-
tient with cleft lip and palate was recently described as
having a balanced reciprocal translocation interrupting
the SUMO1 gene.36 This finding led to the investigation
of Sumo1 down-regulation in the mouse, where cleft lip
or palate was observed in 8.7% of heterozygous Sumo1
gene trap mice (Sumo1gt/) or in 36% of Sumo1gt/, Eya1/
double-heterozygous animals.
The process of SUMO modification is known to be sus-
ceptible to environmental effects that are strikingly similar
to some of the risk factors described for orofacial clefts.1
These include various stresses, such as heat shock and os-
motic and oxidative conditions, which trigger changes
to the cellular SUMO-1 conjugation/deconjugation path-
way.37,38 Severe oxidative stress is usually associated with
an increase in SUMO-1 conjugation,39 but lower, more-
relevant concentrations of free radicals induce an almost
complete loss of SUMO-1 modification of target proteins.37
Another likely influence is viral infection, in which viral
proteins interfere with and down-regulate the activity of
SUMO conjugating enzymes.40,41 Loss of sumoylated sub-
strate leads to an up-regulation of cellular transcription
and is thought to enhance viral replication.41 For clefts of
the lip and palate, a genetic contribution of 20%–50% has
been estimated,42 with the remainder associated with a
wide variety of environmental factors during early preg-
nancy, such as smoking, use of alcohol and chemother-
apeutic drugs, lack of maternal nutritional supplements
such as folic acid or other vitamins, viral infection, and
exposure to agricultural chemicals or other teratogens.1
More-complex factors have also been implicated, includ-
ing maternal age,43 low socioeconomic status,44 psycho-
logical stress in the mother,45,46 altitude,47 and conditions
of hypoxia,48 in some cases with good supporting evidence
provided by animal models.49 It now seems likely that
some of these factors may manifest through disturbance
of the SUMO pathway. Destabilizing the normal balance
of expression and activity for genes such as TBX22, MSX1,
SATB2, and p63 during early pregnancy is likely to provide
a high-risk environment for occurrence of cleft lip and/
or palate. Elucidating the relationship among environ-
mental factors, the SUMO pathway, and the networks of
craniofacial genes that are influenced by this posttran-
scriptional modification may be crucial to our understand-
ing of idiopathic forms of orofacial clefts.
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